Cited by 807Cardiomyopathy and Myosin StudiesCardiovascular Effects of ExerciseViral Infections and Immunology Research

The DOI matches its Crossref record; 518 of the 518 references it cites were found in a registry or an index.

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Ommen, Steve R., Ho, Carolyn Y., Asif, Irfan M., Balaji, Seshadri, Burke, Michael A., Day, Sharlene M., Dearani, Joseph A., Epps, Kelly C., Evanovich, Lauren, Ferrari, Victor A., Joglar, José A., Khan, Sadiya S., Kim, Jeffrey J., Kittleson, Michelle M., Krittanawong, Chayakrit, Martinez, Matthew W., Mital, Seema, Naidu, Srihari S., Saberi, Sara, Semsarian, Christopher, Times, Sabrina, Waldman, Cynthia Burstein·2024·Circulation

DOI 10.1161/cir.0000000000001250

Open this paper in CoChat — free account

Abstract

AIM: The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy” provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy” have been updated with new evidence to guide clinicians.

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000001250

Cites

518 of 518 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2011 Compendium of Physical Activities: A Second Update of Codes and MET Values
AINSWORTH, B. E., HASKELL, W. L., HERRMANN, S. D., MECKES, N., BASSETT, D. R., TUDOR-LOCKE, C., GREER, J. L., VEZINA, J., WHITT-GLOVER, M. C., & LEON, A. S. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31821ece12 · Cited by 6,317
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J., Erdmann, E., Freemantle, N., Gras, D., KAPPENBERGER, L. J., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,300
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Self-citation
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686

Show all 514 references

Research works printed but not linked: 227

Committee on Standards for Systematic Reviews of Comparative Effectiveness Research Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. National Academies Press; 2011.
Animal Studies-Standard-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/54.
Guidelines-Broad-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/75.
Guidelines-Standard-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/77.
RCT/ CCT-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022. Accessed September 14, 2022. https://searchfilters.cadth.ca/link/108.
SR/ MA/ HTA/ ITC-PubMed. In: CADTH Search Filters Database. Ottawa: CADTH; 2022: Accessed September 14, 2022. https://searchfilters.cadth.ca/link/99.
10.1016/s0025-6196(11)64198-0 · DOI
10.1016/j.jacc.2014.05.003 · DOI · Paper page
10.1056/nejmra1710575 · DOI · Paper page
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1001/jamacardio.2015.0354 · DOI · Paper page
10.1056/nejmra1710575 · DOI · Paper page
10.1016/j.jacc.2015.01.019 · DOI
10.1016/j.jacc.2014.05.003 · DOI · Paper page
10.1016/j.jacc.2018.10.007 · DOI
10.1016/j.echo.2010.10.006 · DOI
10.1161/circulationaha.106.644682 · DOI
10.1016/j.amjcard.2017.08.047 · DOI
10.1093/ehjci/jew313 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1016/j.jacc.2013.02.079 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.01.071 · DOI
10.1016/j.jacc.2012.03.076 · DOI
10.1016/j.jacc.2010.11.002 · DOI
10.1016/j.echo.2011.03.006 · DOI
10.1161/circulationaha.107.698985 · DOI
10.1016/j.jcin.2011.02.014 · DOI
10.1016/j.amjcard.2007.09.111 · DOI
10.1161/01.cir.0000097110.55312.bf · DOI
10.1016/j.echo.2010.10.006 · DOI
10.1161/circulationaha.106.644682 · DOI
10.1016/j.amjcard.2017.08.047 · DOI
10.1093/ejechocard/jeq063 · DOI
10.1093/ehjci/jew313 · DOI
10.1136/hrt.2007.126003 · DOI
10.1056/nejmoa021332 · DOI · Paper page
10.1016/s0002-9149(99)80416-0 · DOI
10.1161/01.cir.0000162460.36735.71 · DOI
10.1016/j.jacc.2013.02.079 · DOI
10.1161/hcg.0000000000000054 · DOI
10.1093/eurheartj/ehq271 · DOI
10.1016/j.jacc.2012.02.068 · DOI
10.1161/circgen.117.001896 · DOI · Paper page
10.1161/circulationaha.114.013478 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1016/j.hrthm.2011.07.017 · DOI
10.1161/circulationaha.111.090514 · DOI
10.1161/circgenetics.116.001620 · DOI
10.1161/circulationaha.118.038846 · DOI
10.1016/j.jacc.2015.01.019 · DOI
10.1161/circulationaha.111.090514 · DOI
10.1093/eurheartj/ehz396 · DOI
10.1161/circulationaha.118.037264 · DOI
10.1161/circulationaha.118.038846 · DOI
10.1016/j.jpeds.2017.03.033 · DOI
10.1093/eurheartj/ehr092 · DOI · Paper page
10.1148/radiol.2018180339 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1007/s10554-016-0858-4 · DOI
10.1016/j.amjcard.2016.11.010 · DOI
10.1016/j.amjcard.2010.01.367 · DOI
10.1016/j.jcmg.2016.02.031 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jacc.2018.05.060 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1016/j.echo.2011.03.002 · DOI
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1161/circulationaha.120.047235 · DOI
10.1111/cge.13157 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1093/europace/euz118 · DOI
10.1161/circulationaha.122.062699 · DOI
10.1161/circulationaha.120.047235 · DOI
10.1001/jamacardio.2019.2861 · DOI
10.1001/jamacardio.2018.0789 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1093/europace/euz118 · DOI
10.1177/2047487317702519 · DOI
10.1161/circheartfailure.113.000414 · DOI
10.1016/j.amjcard.2013.12.034 · DOI
10.1111/chd.12286 · DOI
10.1093/eurjpc/zwab181 · DOI
10.1016/j.jacc.2015.03.552 · DOI
10.1111/cge.13157 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/j.jjcc.2014.02.011 · DOI
10.1007/s10554-016-0858-4 · DOI
10.1016/j.amjcard.2016.11.010 · DOI
10.1016/j.amjcard.2010.01.367 · DOI
10.1016/j.jcmg.2016.02.031 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jacc.2018.05.060 · DOI
10.1001/jamacardio.2019.1391 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1016/j.jacc.2020.04.045 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1161/circulationaha.122.062699 · DOI
10.1016/s0735-1097(99)00056-x · DOI
10.1016/j.amjcard.2010.06.077 · DOI · Paper page
10.1056/nejm200006153422403 · DOI
10.1016/s0140-6736(00)04005-8 · DOI
10.1161/circulationaha.108.798314 · DOI · Paper page
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1017/s1047951105001824 · DOI
10.1038/nrcardio.2017.6 · DOI
10.1001/jamacardio.2019.1391 · DOI
10.1001/jama.298.4.405 · DOI
10.1016/j.ahj.2013.06.009 · DOI
10.1016/s0735-1097(99)00056-x · DOI
10.1161/circulationaha.108.798314 · DOI · Paper page
10.1016/j.amjcard.2010.06.077 · DOI · Paper page
10.1093/eurheartj/ehq308 · DOI
10.1056/nejm200006153422403 · DOI
10.1016/j.jacc.2004.12.067 · DOI
10.1016/s0140-6736(00)04005-8 · DOI
10.1161/circulationaha.105.583500 · DOI
10.1016/j.jacc.2016.11.063 · DOI
10.1016/j.jjcc.2014.02.011 · DOI
10.1016/s0735-1097(03)00827-1 · DOI · Paper page
10.1161/circep.116.004604 · DOI
10.1136/heartjnl-2013-305471 · DOI
10.1093/eurheartj/eht439 · DOI · Paper page
10.1016/j.jacc.2020.04.045 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1016/j.jacc.2013.01.037 · DOI
10.1177/2047487317702519 · DOI
10.1007/s00246-011-9967-y · DOI
10.1016/s0735-1097(98)00493-8 · DOI
10.1016/j.jacc.2015.03.552 · DOI
10.1007/s00246-013-0676-6 · DOI
10.1161/circulationaha.115.017633 · DOI
10.1161/circulationaha.120.047235 · DOI
10.1093/eurjpc/zwab181 · DOI
10.1161/circulationaha.113.007094 · DOI · Paper page
10.1016/j.jcmg.2016.02.031 · DOI
10.1016/j.jacc.2018.05.060 · DOI
10.1016/j.amjcard.2013.12.034 · DOI
10.1161/circulationaha.112.136085 · DOI · Paper page
10.1016/j.jacc.2015.02.061 · DOI · Paper page
10.1016/j.amjcard.2020.04.042 · DOI
10.1016/j.hrthm.2019.04.040 · DOI
10.1016/j.jacc.2009.03.051 · DOI
10.1016/j.jacc.2013.01.037 · DOI
10.1161/cir.0000000000001063 · DOI · Paper page
10.1161/cir.0000000000000628 · DOI · Paper page
10.1161/circulationaha.106.644682 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1016/j.jacc.2015.06.1333 · DOI · Paper page
10.1161/circulationaha.106.644682 · DOI
10.1016/j.jacc.2005.02.090 · DOI
10.1016/j.amjcard.2013.01.340 · DOI
10.1016/j.jcmg.2013.08.010 · DOI
10.1001/jamacardio.2016.0252 · DOI
10.1016/j.jtcvs.2018.11.148 · DOI
10.1016/j.mayocp.2018.07.022 · DOI
10.1016/j.jacc.2016.07.735 · DOI · Paper page
10.1016/j.echo.2018.10.011 · DOI
10.1136/hrt.2007.118018 · DOI
10.1161/circulationaha.117.029267 · DOI · Paper page
10.1161/01.cir.0000162460.36735.71 · DOI
Liebregts, M, Vriesendorp, PA, Mahmoodi, BK, et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol HF. 2015;3:896–905.
10.1536/ihj.27.701 · DOI
10.1161/circulationaha.117.033200 · DOI · Paper page
10.1161/01.cir.0000097110.55312.bf · DOI
10.1161/cir.0000000000001063 · DOI · Paper page
10.1161/circulationaha.105.583500 · DOI
10.1093/eurheartj/ehq136 · DOI
10.1161/circheartfailure.114.002248 · DOI · Paper page
10.1253/circj.cj-16-0432 · DOI
10.1016/j.amjcard.2017.12.044 · DOI
10.1016/s0140-6736(20)31792-x · DOI · Paper page
10.1016/j.jacc.2020.04.045 · DOI
10.1016/j.ejheart.2008.03.006 · DOI
Gu, M, Jin, H, Hua, W, et al. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy. J Geriatr Cardiol. 2017;14:238–244.
10.1016/j.jacc.2017.11.040 · DOI
10.1093/europace/euw327 · DOI
Rowin, EJ, Mohanty, S, Madias, C, et al. Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol EP. 2019;5:131–133.
10.1136/heartjnl-2013-305471 · DOI
10.1161/circulationaha.119.044366 · DOI · Paper page
10.1161/circheartfailure.114.001843 · DOI · Paper page
10.1016/s2213-8587(14)70241-4 · DOI
10.1016/j.amjcard.2016.08.092 · DOI
10.1111/jce.12982 · DOI
10.1161/circulationaha.117.029267 · DOI · Paper page
10.1016/j.jacc.2005.01.012 · DOI · Paper page
10.1161/jaha.116.005152 · DOI
10.1016/j.amjcard.2003.10.025 · DOI
10.1016/j.amjcard.2017.12.044 · DOI
10.1161/circheartfailure.114.001435 · DOI
10.1161/circep.110.957290 · DOI

200 of 227 shown

Sorted by citations

JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 275
2024 HRS expert consensus statement on arrhythmias in the athlete: Evaluation, treatment, and return to play
Lampert, R., Chung, E. H., Ackerman, M. J., Arroyo, A. R., Darden, D., Deo, R., Dolan, J., Etheridge, S. P., Gray, B. R., Harmon, K. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.05.018 · Cited by 167
Self-citation
HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America
Fonarow, G. C., Ahmad, F. S., Ahmad, T. A., Albert, N. M., Alexander, K. M., Baker, W. L., Bozkurt, B., Breathett, K. K., Carter, S. J., Cheng, R. K.-H., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.007 · Cited by 103
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Self-citation
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Self-citation
Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy
Desai, M. Y., Owens, A. T., Abraham, T., Olivotto, I., Garcia-Pavia, P., Lopes, R. D., Elliott, P., Fernandes, F., Verheyen, N., Maier, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505927 · Cited by 90
Genes Associated With Hypertrophic Cardiomyopathy
Hespe, S., Waddell, A., Asatryan, B., Owens, E., Thaxton, C., Adduru, M.-L., Anderson, K., Brown, E. E., Hoffman‐Andrews, L., Jordan, E., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.010 · Cited by 86
Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology
Kim, J. H., Baggish, A. L., Levine, B. D., Ackerman, M. J., Day, S. M., Dineen, E. H., Guseh, J. S., Gerche, A. L., Lampert, R. J., Martinez, M. W., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001297 · Cited by 83
Self-citation
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Desai, M. Y., Wolski, K., Owens, A., Geske, J. B., Saberi, S., Wang, A., Sherrid, M., Cremer, P. C., Lakdawala, N. K., Tower-Rader, A., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072445 · Cited by 78
Self-citation
Hypertrophic Cardiomyopathy
Braunwald, E. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2413445 · Cited by 76
Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
Self-citation
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy
Masri, A., Cardoso, R. N., Abraham, T. P., Claggett, B. L., COATS, C. J., Hegde, S. M., Kulac, I. J., Lee, M. M. Y., Maron, M. S., Merkely, B. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.015 · Cited by 68
Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry
Maurizi, N., Antiochos, P., OWENS, A. T., Lakdawala, N. K., Saberi, S., Russell, M. W. W., Fumagalli, C., Skalidis, I., Lin, K. Y., Nathan, A. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069378 · Cited by 61
Self-citation
Artificial intelligence-guided detection of under-recognised cardiomyopathies on point-of-care cardiac ultrasonography: a multicentre study
Oikonomou, E. K., Vaid, A., Holste, G., Coppi, A. C., McNamara, R. L., Baloescu, C., Krumholz, H. M., Wang, Z., Apakama, D. J., Nadkarni, G. N., et al. (2025) · The Lancet Digital Health · doi:10.1016/s2589-7500(24)00249-8 · Cited by 56
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science: A Science Advisory From the American Heart Association
Kim, Y., Landstrom, A. P., Shah, S. H., Wu, J. C., & Seidman, C. E. (2024) · Circulation · doi:10.1161/cir.0000000000001296 · Cited by 51
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Desai, M. Y., Okushi, Y., Gaballa, A., Wang, Q., Geske, J. B., OWENS, A. T., Saberi, S., Wang, A., Cremer, P. C., Sherrid, M. V., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017185 · Cited by 45
Self-citation
Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association
Khan, S. S., Greenland, P., Hayman, L. L., Khera, R., Návar, A. M., Pencina, M. J., Reza, N., Shah, S. H., Shanbhag, S. M., Weber, B., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001401 · Cited by 45
Self-citation
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
Desai, M. Y., Seto, D., Cheung, M., Afsari, S., Patel, N., Bastien, A., Lockman, J., Coiro, M., & Martinez, M. W. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012441 · Cited by 42
Self-citation
2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Gurvitz, M. Z., Krieger, E. V., Fuller, S., Davis, L. L., Kittleson, M. M., Aboulhosn, J., Bradley, E. A., Buber, J., Daniels, C. J., Dimopoulos, K., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001402 · Cited by 38
Self-citation
Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population
Ramonfaur, D., Gasperetti, A., Blake, V., Rivers, B. J., Kassamali, A. A., Kasper, E. K., Barouch, L. A., Wu, K. C., Madrazo, J., & Carrick, R. T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034069 · Cited by 34
Late gadolinium enhancement imaging and sudden cardiac death
Prasad, S. K., Akbari, T., Bishop, M. J., Halliday, B. P., Leyva, F., & Marchlinski, F. E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf464 · Cited by 34
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response
OWENS, A. T., Desai, M. Y., Wheeler, M. T., Rodonski, A., Merali, S. J., Sehnert, A. J., & Saberi, S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.033767 · Cited by 31
Self-citation
The International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014)
Irving, C. A., Azeka, E., Adorisio, R., Blume, E. D., Bogle, C., Chubb, H., Conway, J. L., Cousino, M. K., Edelson, J. B., Ford, K., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.06.003 · Cited by 28
Factors associated with: problems of using exploratory multivariable regression to identify causal risk factors
Lewer, D., Brothers, T. D., O’Nions, E., & Pickavance, J. (2025) · BMJ Medicine · doi:10.1136/bmjmed-2025-001375 · Cited by 27
Current management of hypertrophic cardiomyopathy
Sikand, N., Stendahl, J., Sen, S., Lampert, R., & Day, S. (2025) · BMJ · doi:10.1136/bmj-2023-077274 · Cited by 26
Self-citation
Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―
Kitaoka, H., Ieda, M., Ebato, M., Kozuma, K., Takayama, M., Tanno, K., Komiyama, N., Sakata, Y., Maekawa, Y., Minami, Y., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-24-0501 · Cited by 25
Prognostic Value of Myocardial T1 Mapping for Predicting Adverse Events in Hypertrophic Cardiomyopathy
Wang, J., Zhang, J., Liu, W., Pu, L., Qi, W., Xu, Y., Wan, K., Gkoutos, G. V., Han, Y., & Chen, Y. (2025) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.017174 · Cited by 25
Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy
Davis, B. J., Volk, H., Nguyen, O., Kamna, D., Chen, H., Villa, R. B., García‐Pavía, P., Olivotto, I., OWENS, A. T., COATS, C. J., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038758 · Cited by 25
Advancing Aerobic Exercise Training Intensity Prescription in Health and Disease Beyond Standard Recommendations: A Call to Action
Hansen, D., Cipriano, G., Milani, J. G. P. O., Milani, M., Gojevic, T., Machado, F. V. C., Kambič, T., Eijsvogels, T. M. H., Bonifazi, M., Dendale, P., et al. (2025) · Sports Medicine · doi:10.1007/s40279-025-02272-9 · Cited by 25
Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model
Baka, T., Moore, J., Qin, F., Yurista, S. R., Zhang, A., He, H., Chambers, J. M., Croteau, D., Goel, R. K., Smith, H. R., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf324 · Cited by 22
Hypertrophic Cardiomyopathy: State of the Art
Ommen, S. R., Nishimura, R. A., Schaff, H. V., & Dearani, J. A. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.07.013 · Cited by 19
Self-citation
Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis
Landsteiner, I., Masri, A., Saberi, S., Maron, M. S., McGinnis, S., Griskowitz, C., Newlands, C., Villa, R. B., OWENS, A. T., & Lewis, G. D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039551 · Cited by 19
Self-citation
Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years
Massera, D., Sherrid, M. V., Adlestein, E., Bokhari, N. A., Alvarez, I. C., Wu, W. Y., Reuter, M. C., Maron, M. S., Maron, B. J., & Rowin, E. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037639 · Cited by 19
Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy
Savsin, H., & Tokarek, T. (2025) · Biomedicines · doi:10.3390/biomedicines13071619 · Cited by 18
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy
Xu, A., Weissman, D., Ermer, K. J., Bertero, E., Federspiel, J. M., Stadler, F., Grünler, E., Tangos, M., Zervou, S., Waddingham, M. T., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074120 · Cited by 17
Prediction of New-Onset Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy Using Machine Learning
Lu, R., Lumish, H. S., Hasegawa, K., Maurer, M. S., Reilly, M. P., Weiner, S. D., Tower-Rader, A. F., Fifer, M. A., & Shimada, Y. J. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3546 · Cited by 17
Novel deep learning framework for simultaneous assessment of left ventricular mass and longitudinal strain: clinical feasibility and validation in patients with hypertrophic cardiomyopathy
Park, J., Yoon, Y. E., Jang, Y., Jung, T., Jeon, J., Lee, S., Choi, H., Hwang, I., Chun, E. J., Cho, G., et al. (2025) · Journal of Echocardiography · doi:10.1007/s12574-025-00694-y · Cited by 16
Accelerated Bachmann bundle area pacing for atrial resynchronization in patients with non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction: A randomized crossover trial
Subramanian, M., Yalagudri, S. D., Saggu, D. K., Dillikar, M. V., Singh, J., Bootla, D., Korabathina, R., Chennapragda, S., & Narasimhan, C. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.07.028 · Cited by 16
The Adolescent Athlete and the Team Physician: A Consensus Statement. 2025 Update
Putukian, M., LeClere, L. E., Herring, S., Benjamin, H. J., Bennett, C., Boyajian-O’Neill, L. A., Callender, S. S., Day, M., Finnoff, J. T., Franks, R., et al. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003863 · Cited by 16
Atrial fibrillation burden and management in cardiomyopathies: Current evidence and unmet needs
Antonopoulos, A. S., Kasiakogias, A., Kouroutzoglou, A., Touloupaki, M., Briasoulis, Α., Papatheodorou, E., Rigopoulos, A. G., Antonakaki, D., Laina, A., Tsioufis, K. P., et al. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.01.007 · Cited by 16
A generalizable deep learning system for cardiac MRI
Shad, R., Zakka, C., Kaur, D., Mathur, M., Fong, R., Cho, J., Filice, R. W., Mongan, J., Kallianos, K., Khandwala, N., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01637-3 · Cited by 16
Self-citation
Single-View Echocardiographic Analysis for Left Ventricular Outflow Tract Obstruction Prediction in Hypertrophic Cardiomyopathy: A Deep Learning Approach
Park, J., Kim, J., Jeon, J., Yoon, Y. E., Jang, Y., Jeong, H., Lee, S., Choi, H., Hwang, I., Cho, G., et al. (2025) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2025.08.008 · Cited by 14
Self-citation
Sudden Cardiac Arrest in Athletes
Lampert, R., & Harmon, K. G. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2312555 · Cited by 14
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
Rossano, J. W., Canter, C. E., Wolf, C. M., Papez, A. L., Gambra, M., Bryant, R. M., Alejos, J. C., McCulloch, M. A., Sarquella‐Brugada, G., Bock, M. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601103 · Cited by 14
Self-citation
The impact of diabetes mellitus on cardiac function assessed by magnetic resonance imaging in patients with hypertrophic cardiomyopathy
Yu, S. J., Shi, K., Li, Y., Wang, J., Gao, Y., Shi, R., Yan, W., Xu, H., Guo, Y., & Yang, Z. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02384-y · Cited by 14
Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study
Jung, M., Cho, J. S., Lee, S., Youn, J., Choi, Y., Chung, W., Lee, J., Kang, D., Kwon, W., Kim, T., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae345 · Cited by 14
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy
Desai, M. Y., Olivotto, I., Abraham, T. P., Nissen, S. E., García‐Pavía, P., Lópes, R. D., Elliot, P. M., Fernandes, F., Correia, E. D. B., Villa, R. B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.017 · Cited by 14
Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy
The HCMR Investigators, Kramer, C. M., Kolm, P., DiMarco, J. P., Desai, M. Y., Ho, C. Y., Kwong, R. Y. K., Dolman, S. F., Desvigne-Nickens, P. M., GELLER, N., et al. (2026) · JAMA · doi:10.1001/jama.2026.5633 · Cited by 13
Self-citation
Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review
Kalinski, J. K., Xu, B., Boyd, R. L., Tasseff, N., Rutkowski, K., Ospina, S., Smedira, N., Thamilarasan, M., Popović, Z., & Desai, M. Y. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00667-z · Cited by 13
Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities
Dicorato, M. M., Citarelli, G., Mangini, F., Alemanni, R., Albanese, M., Cicco, S., Greco, C. A., Forleo, C., Basile, P., Carella, M. C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051256 · Cited by 13
Extended ambulatory ECG monitoring enhances identification of higher-risk ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy
Rowin, E. J., Das, G., Madias, C. A., Hsu, M., Crosson, L. A., Turakhia, M. P., Maron, B. J., & Maron, M. S. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.09.040 · Cited by 12
Benefits of Virtual Reality Training for Cardiopulmonary Resuscitation Skill Acquisition and Maintenance
Zhang, N., Ye, G., Yang, C., Zeng, P., Gong, T., Tao, L., Zheng, Y., & Liu, Y. (2024) · Prehospital Emergency Care · doi:10.1080/10903127.2024.2416971 · Cited by 12
Genetic evaluation of early-onset atrial fibrillation: impact on patient management
Laws, J. L., Shabani, M., Williams, H. L., Grauherr, D. D., Kilbourne, W. M., Crawford, D. M., Ogunmola, I., Sun, L., Virk, Z. M., Cathey, B. M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf829 · Cited by 12
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
Desai, M. Y., & Braunwald, E. (2024) · Med · doi:10.1016/j.medj.2024.06.001 · Cited by 12
Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy
Fath, A. R., Aglan, A., Maron, M. S., Phillips, J. S., Maron, B. J., & Rowin, E. J. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133082 · Cited by 11
Family screening for hypertrophic cardiomyopathy: Initial cardiologic assessment, and long-term follow-up of genotype-positive phenotype-negative individuals
Schoonvelde, S. A. C., Alexandridis, G. M., Price, L. B., Schinkel, A. F. L., Hirsch, A., Zwetsloot, P.-P. M., Kammeraad, J. A. E., van Slegtenhorst, M. A., Verhagen, J. M. A., de Boer, R. A., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132951 · Cited by 11
Factors associated with high-intensity physical activity and sudden cardiac death in hypertrophic cardiomyopathy
Lee, H., Gwak, S., Kim, K., Cho, I., Shim, C. Y., Ha, J., & Hong, G. (2025) · Heart · doi:10.1136/heartjnl-2024-324928 · Cited by 11
Predicting New-Onset Atrial Fibrillation in Hypertrophic Cardiomyopathy: A Review
Dicorato, M. M., Basile, P., Naccarati, M. L., Carella, M. C., Dentamaro, I., Falagario, A., Cicco, S., Forleo, C., Guaricci, A. I., Ciccone, M. M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062018 · Cited by 11
Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications
Choi, E., Chung, H., & Lee, K. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00055-4 · Cited by 11
Surgical myectomy for hypertrophic cardiomyopathy: procedural volume and outcomes
Heeringa, T. J. P., Hegeman, R. R. M. J. J., Koop, Y., el Mathari, S., Hoogewerf, M., Roefs, M. M., Smits, K. C., Laenens, D., Zan, G. D., Cramer, M. J., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf560 · Cited by 11
The Evolving Role of Cardiac Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Prognosis, and Clinical Practice
Dentamaro, I., Dicorato, M. M., Falagario, A., Cicco, S., Dentamaro, S., Correale, M., Manuppelli, V., Citarelli, G., Mangini, F., Fiore, C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092138 · Cited by 11
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks
Desai, M. Y., Okushi, Y., Wolski, K., Geske, J. B., OWENS, A. T., Wang, Q., Saberi, S., Wang, A., Cremer, P. C., Lakdawala, N. K., et al. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.07.019 · Cited by 11
Self-citation
Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study
Desai, M. Y., Szpakowski, N., Tower-Rader, A. F., Bittel, B., Fava, A. M., Ospina, S., Xu, B., Thamilarasan, M., Mentias, A. G., Smedira, N. G., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037058 · Cited by 11
The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Skórka, P., Piotrowski, J., Bakinowska, E., Kiełbowski, K., & Pawlik, A. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm27152 · Cited by 12
Hypertrophic Cardiomyopathy: Genes and Mechanisms
Chen, J., Yang, X., Sun, J., Liu, Y., Lang, Z., Zhang, L., & Yang, J. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25714 · Cited by 11
Deep learning of echocardiography distinguishes between presence and absence of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy
Akita, K., Kusunose, K., Haga, A., Shimomura, T., Kosaka, Y., Ishiyama, K., Hasegawa, K., Fifer, M. A., Maurer, M. S., & Shimada, Y. J. (2024) · Echo Research and Practice · doi:10.1186/s44156-024-00059-8 · Cited by 10
Hypertrophic Cardiomyopathy as a Form of Heart Failure with Preserved Ejection Fraction: Diagnosis, Drugs, and Procedures
Banthiya, S., Check, L., & Atkins, J. (2024) · US Cardiology Review · doi:10.15420/usc.2023.21 · Cited by 10
Procedural Volume and Outcomes After Septal Reduction Therapies in Hypertrophic Obstructive Cardiomyopathy
Patel, N. B., Shetty, N. S., Gaonkar, M. P., Shahid, A., Divekar, G., Pampana, A., Vekariya, N., Li, P., Ahmed, M. I., Arora, G., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036387 · Cited by 10
Advances in Cardiac Imaging and Genetic Testing for Diagnosis and Risk Stratification in Cardiomyopathies: 2024 Update
Gąsior, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237166 · Cited by 10
Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants
Ricci, F., Molinari, L. V., Mansour, D., Galanti, K., Vagnarelli, F., Renda, G., Gallina, S., OWENS, A. T., Luzum, J. A., Olivotto, I., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.11.041 · Cited by 10
Arrhythmias and Sudden Death: What is New in Hypertrophic Cardiomyopathy?
Rajan, D., Zörner, C. R., Hansen, M. L., & Tfelt‐Hansen, J. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.38 · Cited by 10
Advanced Diagnosis of Hypertrophic Cardiomyopathy with AI-ECG and Differences Based on Ethnicity and HCM Subtype
Lewontin, M., Kaplan, E., Bilchick, K. C., Barber, A., Bivona, D. J., Kramer, C. M., Parrish, A., McClean, K., Thomas, M., Perry, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134718 · Cited by 10
Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges
Kukowka, A., & Droździk, M. (2025) · Biomolecules · doi:10.3390/biom15081098 · Cited by 10
Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification
Desai, M. Y., Gaballa, A., Okushi, Y., Abusafia, M., Jadam, S., Rutkowski, K., Ospina, S., Sultana, S., Thamilarasan, M., Asher, C. R., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044537 · Cited by 10
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
Masri, A., Maron, M. S., Bhatia, A., Peña‐Peña, M. L., Sherrid, M. V., Figueiredo, E. L., Arad, M., Barriales-Villa, R., Choudhury, L., Claggett, B. L., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603021 · Cited by 11
Self-citation
The diagnosis and treatment of hypertrophic cardiomyopathy
Möbius-Winkler, M. N., Laufs, U., & Lenk, K. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0196 · Cited by 10
Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Scholtz, S., Coppée, C., Mohemed, K., Potratz, M., Sequeira, V., Rudolph, V., Scholtz, W., & Reil, J. (2025) · Open Heart · doi:10.1136/openhrt-2025-003192 · Cited by 10
Diastolic Stress Echocardiography in Patients With Hypertrophy Cardiomyopathy: Association With Exercise Capacity
Fava, A. M., Popović, Z., Alashi, A., Thamilarasan, M., Xu, B., & Desai, M. Y. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.09.017 · Cited by 9
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Samhan, A., Saleh, D., Kim, E. Y., Hu, M., Mueller, K., Garza, A., Schormann, E., Bindra, P. H., Cheema, B. S., Fullenkamp, D. E., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.12.024 · Cited by 9
Medical, Surgical, and Interventional Management of Hypertrophic Cardiomyopathy
Massera, D., Sherrid, M. V., Scheinerman, J. A., Swistel, D. G., & Razzouk, L. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.124.014023 · Cited by 9
Update on left ventricular outflow tract obstruction
Song, J.-K., Sun, B. J., Kim, D., & Jung, S. H. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00049-2 · Cited by 9
Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy
Mahana, I., Mejia, A. T., Elman, M., Kamna, D., Nguyen, O., Volk, H., Chen, H., & Masri, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042488 · Cited by 9
Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025
Wilk, M. M., & Tymków, R. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120484 · Cited by 9
Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023
Butzner, M., ElHabr, A. K., Farajkhah, K., Chhatwal, J., Ayer, T., Gebrehiwet, P., Shreay, S., Riello, R. J., Desai, N. R., OWENS, A. T., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102552 · Cited by 9
Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies
Maron, B. J., Ommen, S. R., Nishimura, R. A., McKenna, W. J., Rakowski, H., Sherrid, M. V., Olivotto, I., Braunwald, E., & Maron, M. S. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047462 · Cited by 9
Self-citation
An Improved Approach for Cardiac MRI Segmentation based on a 3D UNet Combined with Papillary Muscle Exclusion
Benameur, N., Mahmoudi, R., Deriche, M. A., Fayouka, A., Masmoudi, I., & Zoghlami, N. (2025) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-025-10310-x · Cited by 9
Hypertrophic cardiomyopathy: current understanding and emerging therapeutics
Dai, J., Da, Z., Taramasso, M., Pan, X., & Wang, D. W. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100073 · Cited by 8
Relationship Between Cardiac Troponin I Concentration and Myocardial Function in Hypertrophic Cardiomyopathy Cats With or Without Left Ventricular Outflow Tract Obstruction
Satomi, S., Suzuki, R. H., Yuchi, Y., Yoshii, Y., Kanno, H., Teshima, T., & Matsumoto, H. (2025) · Animals · doi:10.3390/ani15091313 · Cited by 8
Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis
Awad, K., Pereyra, M., Farina, J., Pathangey, G., Abbas, M. T., Scalia, I. G., Couteur, D. G. L., Wilanksy, S., Lester, S. J., Ommen, S. R., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf036 · Cited by 8
Self-citation
Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy
Kim, K. A., & Jung, M. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00050-9 · Cited by 8
Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation
Zampieri, M., Saberi, S., D’Ascenzi, F., Papadakis, M., Pelliccia, A., & Olivotto, I. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf770 · Cited by 8
Self-citation
EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy
Meder, B., COATS, C. J., Leinwand, L. A., Pieroni, M., García‐Pavía, P., Desai, M. Y., & Sedaghat‐Hamedani, F. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf008 · Cited by 8
Vigorous exercise and sports participation in individuals with hypertrophic cardiomyopathy
Gray, B. R., Ackerman, M. J., Link, M. S., & Lampert, R. J. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.09.004 · Cited by 8
Comparative Influences of Beta blockers and Verapamil on Cardiac Outcomes in Hypertrophic Cardiomyopathy
Pinto, G., Chiarito, M., Puscas, T., Bacher, A., Donal, E., Réant, P., Condorelli, G., & Hagège, A. A. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.10.029 · Cited by 8
H2FPEF and HFA-PEFF Scores for Heart Failure Risk Stratification in Hypertrophic Cardiomyopathy Patients
Gao, Y.-P., Liu, H.-Y., Bi, X.-J., Sun, J., Zhu, Y., Zhou, W., Fan, Y.-T., Cheng, X.-Q., Huang, P., Liu, Y., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15247 · Cited by 8
ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’
Chimenti, C., Iacovoni, A., Montalto, A., Emdin, M., Olivotto, I., Basso, C., Chiara, B. C. D., Bottillo, I., Ciampi, C. M., Dellegrottaglie, S., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf077 · Cited by 7
Lung‐Derived Small Extracellular Vesicles Containing miR‐15a‐5p/miR‐96‐5p Promote Myocardial Fibrosis in Hypertrophic Cardiomyopathy via Targeting SMAD7
Long, M., Sun, J., Zhou, D., Chen, C., Shu, J., Mao, X., Yu, K., Liang, M., Chen, L., Wang, Y., et al. (2025) · Small · doi:10.1002/smll.202501610 · Cited by 7
Evaluation of sudden cardiac death in hypertrophic cardiomyopathy
Yoon, S. G., & Hong, G. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00054-5 · Cited by 7
Incremental prognostic value of epicardial adipose tissue volume and thickness assessed by cardiac MRI in hypertrophic cardiomyopathy
Song, Y., Hu, M., Ren, H., Fang, Q., Zheng, T., Feng, Z., Wang, X., Xu, L., & Gong, L. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf305 · Cited by 7

Authors: Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., Joglar, J. A., Khan, S. S., Kim, J. J., Kittleson, M. M., Krittanawong, C., Martinez, M. W., Mital, S., Naidu, S. S., Saberi, S., Semsarian, C., Times, S., & Waldman, C. B.
Affiliations: American Medical Society for Sports Medicine (US)
HRS representative.
Lay stakeholder representative.
AHA/ACC Joint Committee on Clinical Practice Guidelines liaison.
American Hospital Association (US)
PACES representative.
Joint ACC/AHA staff representative.
ORCID: Ommen, Steve R.
Ho, Carolyn Y.
Asif, Irfan M.
Balaji, Seshadri
Burke, Michael A.
Day, Sharlene M.
Dearani, Joseph A.
Ferrari, Victor A.
Joglar, José A.
Khan, Sadiya S.
Kim, Jeffrey J.
Kittleson, Michelle M.
Krittanawong, Chayakrit
Martinez, Matthew W.
Mital, Seema
Naidu, Srihari S.
Saberi, Sara
Semsarian, Christopher
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2024-06-04
Volume: 149
Issue: 23
Pages: e1239-e1311
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/cir.0000000000001250
OpenAlex: W4396750647
Cited by: 807
References: 514
Citations by year: 2026: 353 · 2025: 372 · 2024: 82
FWCI: 226.55
Type: journal article
Language: en
Update notices: correction (2024-08-19)
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Effects of Exercise
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Keywords: hypertrophic cardiomyopathy, disease management, inherited heart disease, diagnosis, treatment guidelines, American Heart Association, American College of Cardiology, American Society of Echocardiography
MeSH terms: American Heart Association, Cardiology, Cardiomyopathy, Hypertrophic, Humans, United States, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks